Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on February 7, 2013, covering events occurring on February 1, 2013. The filing announces the commercial launch of Oxtellar XR, a novel once-daily extended-release antiepileptic drug, and details a material supply agreement entered into in August 2012.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses on operational milestones and contractual agreements rather than financial performance data.
Material Changes and Events
- Commercial Launch: Oxtellar XR tablets were commercially launched in the United States on February 4, 2013, following FDA approval received on October 19, 2012.
- Sales Force Deployment: A sales force of approximately 75 representatives began promoting the product on February 4, 2013.
- Supply Agreement: The Company entered into a Commercial Supply Agreement with Patheon, Inc. effective August 23, 2012, to manufacture, formulate, and supply commercial-grade quantities of the product.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the product launch and the activation of the sales force. The filing notes that the supply agreement was executed in anticipation of FDA approval and the subsequent commercial launch. No specific forward-looking guidance, risk factors, or contingencies are detailed within the text of this specific filing, other than the standard reference to the full text of the supply agreement for complete terms.
Investor Verification Checklist
- Verify the terms of the Commercial Supply Agreement with Patheon, Inc. (Exhibit 10.1), noting that portions are redacted under confidential treatment.
- Review the press release (Exhibit 99.1) for detailed indications and target demographics for Oxtellar XR.
- Monitor future filings for initial revenue recognition and sales performance following the February 4, 2013 launch.
- Confirm the operational status of the 75-person sales force and initial market penetration rates.